Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study.
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Artemisinins, the most effective antimalarials available, are not recommended for falciparum malaria during the first trimester of pregnancy because of safety concerns. Therefore, quinine is used despite its poor effectiveness. Assessing artemisinin safety requires weighing the risks of malaria and its treatment. We aimed to assess the effect of first-trimester malaria and artemisinin treatment on miscarriage and major congenital malformations. METHODS: In this observational study, we assessed data from antenatal clinics on the Thai-Myanmar border between Jan 1, 1994, and Dec 31, 2013. We included women who presented to antenatal clinics during their first trimester with a viable fetus. Women were screened for malaria, and data on malaria, antimalarial treatment, and birth outcomes were collected. The relationship between artemisinin treatments (artesunate, dihydroartemisinin, or artemether) and miscarriage or malformation was assessed using Cox regression with left-truncation and time-varying exposures. FINDINGS: Of 55 636 pregnancies registered between 1994 and 2013, 25 485 pregnancies were analysed for first-trimester malaria and miscarriage, in which 2558 (10%) had first-trimester malaria. The hazard of miscarriage increased 1·61-fold after an initial first-trimester falciparum episode (95% CI 1·32-1·97; p<0·0001), 3·24-fold following falciparum recurrence (2·24-4·68; p<0·0001), and 2·44-fold (1·01-5·88; p=0·0473) following recurrent symptomatic vivax malaria. No difference was noted in miscarriage in first-line falciparum treatments with artemisinin (n=183) versus quinine (n=842; HR 0·78 [95% CI 0·45-1·34]; p=0·3645) or in risk of major congenital malformations (two [2%] of 109 [95% CI 0·22-6·47] versus eight (1%) of 641 [0·54-2·44], respectively). INTERPRETATION: First-trimester falciparum and vivax malaria both increase the risk of miscarriage. We noted no evidence of an increased risk of miscarriage or of major congenital malformations associated with first-line treatment with an artemisinin derivative compared with quinine. In view of the low efficacy of quinine and wide availability of highly effective artemisinin-based combination therapies, it is time to reconsider first-trimester antimalarial treatment recommendations. FUNDING: The Wellcome Trust and The Bill & Melinda Gates Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Association between initial and recurrent first-trimester malaria and miscarriage Models include women lost to follow-up before 28 weeks (until gestation time last seen), but percentage calculations for delivered or miscarried do not. Models for falciparum malaria (1–4) include women that might have also had first-trimester vivax, malariae, or ovale malaria. See appendix p 8 for associations in women with only first-trimester falciparum malaria. Models for vivax malaria (5–6) exclude women who also had first-trimester falciparum malaria. Models 2 and 5 exclude women with symptomatic malaria. Models 3 and 6 exclude women with asymptomatic infections. Model 4 excludes women with uncomplicated infections. Models were adjusted for year (by stratification due to non-proportional hazards [p<0·001]), gravidity, current smoking status, and non-malaria febrile morbidity in first trimester. Age and previous miscarriage were omitted from multivariable models due to collinearity with gravidity. Adjusted results for gravidity, current smoking status, and febrile morbidity in first trimester are shown from Model 1. 146 women had recurrent first-trimester falciparum malaria (136 had two and ten had three episodes). 13 women had recurrent (two) asymptomatic first-trimester falciparum malaria. 81 women had recurrent symptomatic first-trimester falciparum malaria (75 had two, and six had three episodes). 17 women had recurrent (two episodes) asymptomatic fi0rst-trimester vivax malaria, and none miscarried. 38 women had recurrent (two) symptomatic first-trimester vivax malaria. See appendix p 8 for a table version of this figure, including univariable associations.](https://figures.cochat.ai/paper-figures/4d790ee769cb40c08aea511918093d60/safety-of-artemisinins-in-first-trimester-of-prospectively-followed-pregnancies-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cohort has demonstrated the strong association between malaria (both P. falciparum and P. vivax) during pregnancy and severe adverse pregnancy outcomes such as maternal anaemia, foetal loss including miscarriage, 241 stillbirth and neonatal mortality, 83”
From Cohort Profile: the SMRU Refugee and Migrant Pregnancy Study in Western Thailand and Eastern Myanmar (2026) · cites this paper as [241]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The finding that people with malaria travel longer distances to access care may be related to the high rates of loss to follow-up in people with malaria, noted by Moore et al. [32].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology
Salas, M., Hotman, A., & Stricker, B. H. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009758 · Cited by 471
Diagnostic Criteria for Nonviable Pregnancy Early in the First Trimester
Doubilet, P. M., Benson, C. B., Bourne, T., & Blaivas, M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1302417 · Cited by 414
Malaria during pregnancy in an area of unstable endemicity.
Nosten, F., ter Kuile, F., Maelankirri, L., Decludt, B., & White, N. J. (1991) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(91)90205-d · Cited by 294
Self-citationMcGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228
Self-citationMcGready, R., Cho, T., Keo, N. K., Thwai, K. L., Villegas, L., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Clinical Infectious Diseases · doi:10.1086/324349 · Cited by 178
Self-citationThe Effects of Mefloquine Treatment in Pregnancy
Nosten, F. H., Vincenti, M., Simpson, J. A., Yei, P., Thwai, K. L., de Vries, A., Chongsuphajaisiddhi, T., & White, N. J. (1999) · Clinical Infectious Diseases · doi:10.1086/515183 · Cited by 137
Self-citationClark, R. L. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2009.05.002 · Cited by 124
The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy
Deen, J. L., von Seidlein, L., Pinder, M., Walraven, G. E. L., & Greenwood, B. M. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90204-4 · Cited by 102
Meister, R., & Schaefer, C. (2008) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.06.006 · Cited by 102
McGready, R., Boel, M., Rijken, M. J., Ashley, E. A., Cho, T., Moo, O., Paw, M. K., Pimanpanarak, M., Hkirijareon, L., Carrara, V. I., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040244 · Cited by 101
Self-citation
Cited by
Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem
Rogerson, S. J., Desai, M., Mayor, A., Sicuri, E., Taylor, S. M., & van Eijk, A. M. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30066-5 · Cited by 306
Moore, K. A., Simpson, J. A., Wiladphaingern, J., Min, A. M., Pimanpanarak, M., Paw, M. K., Raksuansak, J., Pukrittayakamee, S., Fowkes, F. J. I., White, N. J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0877-6 · Cited by 111
“However, in a previous analysis of SMRU antenatal data, malaria detected and treated in the first trimester was strongly associated with miscarriage [31], and in this analysis, malaria detected and treated from 12 weeks’ gestation was associated with preterm birth and/or SGA, regardless of the presence of symptoms.”
BackgroundResultSelf-citationDellicour, S., Sevene, E., McGready, R., Tinto, H., Mosha, D., Manyando, C., Rulisa, S., Desai, M., Ouma, P., Oneko, M., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002290 · Cited by 90
Self-citationMoore, K. A., Fowkes, F. J. I., Wiladphaingern, J., Wai, N. S., Paw, M. K., Pimanpanarak, M., Carrara, V. I., Raksuansak, J., Simpson, J. A., White, N. J., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0863-z · Cited by 83
Self-citationSteinbrook, E., Min, M. C., Kajeechiwa, L., Wiladphaingern, J., Paw, M. K., Pimanpanarak, M. P. J., Hiranloetthanyakit, W., Min, A. M., Tun, N. W., Gilder, M. E., et al. (2021) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-021-04276-5 · Cited by 46
Self-citation
Metadata
- Authors
- Moore, K. A., Simpson, J. A., Paw, M. K., Pimanpanarak, M., Wiladphaingern, J., Rijken, M. J., Jittamala, P., White, N. J., Fowkes, F. J. I., Nosten, F., & McGready, R.
- Affiliations
- Burnet Institute (AU)
- The University of Melbourne (AU)
- Mahidol University (TH)
- Corresponding author
- Moore, Kerryn A
- ORCID
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 16
- Issue
- 5
- Pages
- 576-583
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC4835584
- OpenAlex
- W2261876003
- Semantic Scholar
- 6cd91d74516b649d22dd7fc57bf00af6617107bd
- Cited by
- 84
- References
- 30
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 1 · 2023: 7 · 2022: 5 · 2021: 6 · 2020: 23 · 2019: 6 · 2018: 8 · 2017: 12 · 2016: 11
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-05-01)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Greater South Information System
- Funders
- Bill and Melinda Gates Foundation (46589)
- Burnet Institute
- Wellcome Trust (093956, 093956/Z/10/Z)
- Australian Government
- Mahidol University
- Australian Research Council
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- artemisinin, first trimester, falciparum malaria, miscarriage, major congenital malformations, artemether, dihydroartemisinin, artesunate, quinine, antimalarial drug safety, Thai-Myanmar border, birth outcomes
- MeSH terms
- Abortion, Spontaneous, Adolescent, Adult, Antimalarials, Female, Humans, Pregnancy, Pregnancy Complications, Pregnancy Trimester, First, Quinine, Thailand, Malaria, Falciparum, Malaria, Vivax, Artemisinins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. https://app.cochat.ai/papers/10.1016/s1473-3099(15)00547-2
- The paper
- Moore, K. A., Simpson, J. A., Paw, M. K., Pimanpanarak, M., Wiladphaingern, J., Rijken, M. J., Jittamala, P., White, N. J., Fowkes, F. J. I., Nosten, F., & McGready, R. (2016). Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(15)00547-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.